Seven \$1 billion-plus drugs seen reaching market in 2016 | Reuters



Business | Wed Feb 3, 2016 4:21am EST

Related: HEALTH

Seven \$1 billion-plus drugs seen reaching market in 2016



Pharmaceutical tablets and capsules in foil strips are arranged on a table, in this file photo illustration shot in Ljubljana on September 18, 2013. REUTERS/SRDJAN ZIVULOVIC/FILES

Drug companies are likely to launch seven "blockbuster" drugs in 2016, each with \$1 billion-plus annual sales potential, led by new treatments for liver disease and HIV, according to a Thomson Reuters analysis.

The assessment means the pharmaceuticals industry is on track for another productive year, although not as good as 2015, which saw the arrival of 11 new blockbusters.

The two top hits of 2016 are tipped to be Intercept Pharmaceuticals' (ICPT.O) chronic liver disease drug obeticholic acid, with a consensus sales forecast of \$2.6 billion in 2020, and Gilead Sciences' (GILD.O) new fixed dose HIV drug emtricitabine plus tenofovir alafenamide, on \$2.0 billion.

Other products expected to launch this year with forecast sales above \$1 billion in 2020 include a new hepatitis C drug from Merck (MRK.N) and a leukemia medicine from AbbVie (ABBV.N), according to the annual "Drugs to Watch" report.

Two keenly awaited Roche ROG.VX drugs, each with forecast sales of around \$3 billion, are not on list because it is unclear if atezolizumab for cancer and ocrelizumab for multiple sclerosis will be commercially available this year or next.

(Reporting by Ben Hirschler Editing by Jeremy Gaunt)



PHOTOS OF THE DAY



IN PHOTOS: VICTORY DAY



Commemorating the former Soviet Union's victory over Nazi Germany in World War II. Slideshow »



from the App Store



Find authenticated court documents without watermarks at docketalarm.com.

TRENDING ON REUTERS	
Trump retreats on comments on raising taxes on the wealthy I VIDEO	1
North Carolina officials sue Justice Department over transgender 'bathroom law' VIDEO	2
Brazil Senate moves forward with impeachment process	3
Japanese court rules vagina figurines 'pop art', not obscenity	4
Russian firm milks chilly US-Kremlin ties with 'Little Obama' ice cream	5

Follow Reuters 🌒 f 🔊 🖸 🗈 in

More from Reuters Newsletters Podcasts Mobile Apps

News and Media Division of Thomson Reuters

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an <u>Editorial Handbook</u> which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

© 2016 Reuters All Rights Reserved

Site Feedback Corrections Advertise With Us Advertising Guidelines AdChoices Terms of Use Privacy Policy Copyright